Author

A. Latif

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

A. M. Rieger· 1 shared A. P. Bhavsar· 1 shared A. Stevens· 1 shared A. Tirella· 1 shared A. Ufuk· 1 shared C. Delyea· 1 shared E. Mancuso· 1 shared G. Babolmorad· 1 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

A. M. Rieger

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Invasion and Secondary Site Colonization as a function of In vitro Primary Tumor Matrix Stiffness

L. Shah, A. Latif, K. J. Williams, E. Mancuso, A. Tirella

This study investigates how breast tissue stiffness affects cancer cell invasion and bone metastasis using in vitro models.

bioRxiv · Jul 22, 2022 · PreprintBioengineering

Monocarboxylate Transporters are Involved in Extracellular Matrix Remodelling in Pancreatic Ductal Adenocarcinoma

A. Ufuk, T. Garner, A. Stevens, A. Latif

This paper investigates the role of monocarboxylate transporters (MCTs) in extracellular matrix (ECM) remodelling in pancreatic ductal adenocarcinoma (PDAC) using RNA-sequencing data and hypernetwork analysis, revealing bidirectional associations between MCTs and ECM components.

Cancers · Mar 2, 2022Peer-reviewedCancer Biology

Toll-like receptor 4 is activated by platinum and contributes to cisplatin-induced ototoxicity

G. Babolmorad, A. Latif, N. M. Pollock, I. K. Domingo, C. Delyea, A. M. Rieger, W. T. Allison, A. P. Bhavsar

This paper shows platinum and cisplatin activate TLR4, contributing to ototoxicity, and identifies TLR4 as a target to mitigate cisplatin-induced hearing loss.

The EMBO Reports · Mar 18, 2021Peer-reviewedPharmacology & Toxicology